NCT00974181View on ClinicalTrials.gov

The European Cobalt STent With Antiproliferative for Restenosis Trial (EuroSTAR Trial)

PHASE3CompletedINTERVENTIONAL
Enrollment

282

Participants

Timeline

Start Date

January 31, 2004

Primary Completion Date

May 31, 2005

Study Completion Date

March 31, 2010

Conditions
Treatment of Symptomatic Ischemic Heart Disease
Interventions
DEVICE

Conor Medsystems COSTAR™ stent (10 µg Paclitaxel)

Intervention will consist of percutaneous coronary intervention for treatment of one or more de-novo coronary lesion(s) using standard coronary intervention techniques. Intervention in this arm will include treatment with the CoStar™ Paclitaxel-Eluting Coronary Stent System (10 µg Paclitaxel)

DEVICE

Conor Medsystems COSTAR™ stent (30 µg Paclitaxel)

Intervention will consist of percutaneous coronary intervention for treatment of one or more de-novo coronary lesion(s) using standard coronary intervention techniques. Intervention in this arm will include treatment with the CoStar™ Paclitaxel-Eluting Coronary Stent System (30 µg Paclitaxel)

Trial Locations (1)

Unknown

EMO Centro Cuore Columbus, Milan

Sponsors

Lead Sponsor

Cordis Corporation

Collaborators (1)

Conor Medsystems
All Listed Sponsors
collaborator

Conor Medsystems

INDUSTRY

lead

Cordis Corporation

INDUSTRY